

HETEROCYCLES, Vol. 94, No. 3, 2017, pp. 503 - 514. © 2017 The Japan Institute of Heterocyclic Chemistry
Received, 14th December, 2016, Accepted, 28th February, 2017, Published online, 17th March, 2017
DOI: 10.3987/COM-16-13638


SYNTHESIS OF 6,7-DIHYDRO-9,10-DIMETHOXYDIBENZO[*a,f*]QUINOLIZINIUM SALT AND ITS D-RING SUBSTITUTED DERIVATIVES

Kazuo Yamazaki, Mai Aritake, Shungo Takamoto, Midori Tabata, Sachiko Yanagihara, Keisuke Uji, Kazuaki Ohyama, Kei Ogiso, Takumi Sugahara, Ai Tatara, Tetsuji Hosono, Keitaro Suzuki, and Masashi Ohba*


Yokohama University of Pharmacy, Matano-cho, Totsuka-ku, Yokohama 245-0066, Japan; E-mail: m.ohba@hamayaku.ac.jp

Abstract – Synthesis of 6,7-dihydro-9,10-dimethoxydibenzo[*a,f*]quinolizinium salt (**2a**) and its derivatives (**2b–g**) substituted at the D ring has been achieved from 3-(2-bromoaryl)propanoic acid (**3**) in four steps for future examination of the inhibitory activity of these compounds against topoisomerase. The dihydrocarbostyrils (**5a–g**), key intermediates in this synthetic scheme, were prepared from the amides (**4a–g**) *via* intramolecular aryl amidation reactions.

The dibenzo[*a,f*]quinolizinium skeleton (**1**) has long been known as one of the seven theoretically possible dibenzoquinolizinium compounds.¹ Although the Bischler–Napieralski cyclization of an *N*-arylethylated carbostyril or dihydrocarbostyril moiety has been mainly employed to form the B ring of this skeleton,¹ several alternative routes have also been reported.² The synthesis of 6,7-dihydro-9,10-dimethoxydibenzo[*a,f*]quinolizinium iodide (**2a**), a prototype of this ring system, was performed by Fujii and co-workers *via* mercuric acetate–edetic acid oxidation of a tetrahydroquinoline and subsequent cyclization of the resulting dihydrocarbostyril.³ On preliminary examination of the inhibitory activity against topoisomerase I, the quinolizinium iodide (**2a**) showed a moderate effect (IC₅₀ = 13.9 μM).⁴ Therefore, the synthesis of 6,7-dihydro-9,10-dimethoxydibenzo[*a,f*]quinolizinium salts (**2a–g**) bearing different substituents on the D ring was undertaken for future structure–activity relationship (SAR) studies.



We envisioned the dihydrocarbostyryl (**5**) as a key intermediate in the synthesis of various dibenzoquinolizinium salts (**2**), as the lactam structure such as **5** would be available through the intramolecular aryl amidation reaction⁵ of the amide (**4**), and also because conversion of **5** into the iminium salt (**7**) is feasible *via* the Bischler–Napieralski reaction described above. Thus, the amides (**4a–g**) required for the preparation of **5** were obtained from a variety of 3-(2-bromoaryl)propanoic acids (**3a–g**) in good yields through condensation with homoveratrylamine.




The intramolecular aryl amidation reaction⁵ of the amide (**4**) was first investigated using the method of Buchwald.^{5a} Thus, treatment of **4a** with Pd₂(dba)₃, P(*o*-tolyl)₃, and K₂CO₃ in toluene at 100 °C provided the dihydrocarbostyryl (**5a**)³ in 50% yield. In contrast, the intramolecular *N*-arylation of **4a** using copper (CuI, *N,N*-dimethylethylenediamine, and K₂CO₃ in toluene at 110 °C) instead of palladium as a transition metal catalyst, an application of intermolecular version,⁶ proved less effective. Best results were obtained when the amide (**4a**) was heated with Pd₂(dba)₃, *t*-Bu₃PHBF₄, and *N,N*-dicyclohexylmethylamine in DMF at 100 °C;⁷ under these conditions, the desired product (**5a**) was produced in 77% yield. In a similar fashion, other dihydrocarbostyryls (**5b–g**) were prepared in moderate yields from the amides (**4b–g**), respectively.

For the conversion of **5** into the dibenzoquinolizinium salts (**2a–g**), we initially examined the oxidation of

5 followed by the Bischler–Napieralski cyclization of the resulting carbostyryl (**6**), because a few precedents for the cyclization of carbostyryls had been found in the literature.^{1c,fb} Oxidation of **5b** with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ), a versatile reagent for the dehydrogenation of carbonyl compounds to give α,β -unsaturated congeners,⁸ proceeded smoothly at 80 °C to provide **6b** in 79% yield. However, similar treatment of **5c** failed to give the desired carbostyryl (**6c**). The mechanism of dehydrogenation by DDQ involves an initial rate-determining transfer of a hydride ion to the quinone oxygen, followed by a rapid proton transfer to the hydroquinone ion.⁸ It is likely that the incipient benzylic carbonium ion derived from **5b** is stabilized effectively by the 7-methoxy group, whereas such stabilization is unlikely in the carbonium ion arising from **5c**. Indeed, oxidation of **5f** and **5g** bearing electron-donating substituents at the 7-position proceeded as expected, providing **6f** and **6g** in 81% and 74% yields, respectively. In addition, conversion of **6b** into the dibenzoquinolizinium chloride (**2b**: X = Cl) in 46% yield was achieved in refluxing POCl₃ by means of the Bischler–Napieralski cyclization.

As the oxidation of **5** was found to depend on the substitution pattern of its dihydrocarbostyryl ring, we next investigated the cyclization of **5** and subsequent oxidation of the resulting iminium salt (**7**). The Fujii group previously reported that the cyclization of **5a** with POCl₃ followed by treatment of crude **7a** with KI afforded **2a** (X = I), instead of **7a** (X = I), in 38% yield accompanying the tetracyclic base (**8**) due to the disproportionation of **7a** (X = Cl or I).³ Therefore, to obtain the desired ring system (**2**) alone, the iminium salt (**7a**), derived from **5a** via cyclization with POCl₃ in refluxing toluene, was treated with 0.5 M aqueous I₂/KI at 0 °C for 30 min to give the 6,7-dihydrodibenzo[*a,f*]quinolizinium triiodide (**2a**: X = I₃) in 87% yield from **5a**. On similar treatment of the dihydrocarbostyryls (**5c–g**), the corresponding dibenzoquinolizinium triiodides (**2c–g**: X = I₃) were prepared in good yields.



In conclusion, 6,7-dihydro-9,10-dimethoxydibenzo[*a,f*]quinolizinium salt (**2a**) and its derivatives (**2b–g**) bearing a range of different substituents on the D ring were successively prepared from the dihydrocarbostyryls (**5a–g**) through either a cyclization–dehydrogenation route (**2a,c–g**) or a dehydrogenation–cyclization route (**2b**). The inhibitory activities of **2a–g** against topoisomerase will be reported elsewhere.

EXPERIMENTAL

General Notes. All melting points were taken on a Yamato MP-21 capillary melting point apparatus. Flash chromatography was carried out by using Merck silica gel 60 (No. 9385). The ratios of solvents in mixtures are shown in v/v. Spectra reported herein were recorded on a JEOL JMS-700 mass spectrometer, a Perkin-Elmer Spectrum 100 FT-IR spectrometer, or a JEOL JNM-ECA500 (¹H 500 MHz, ¹³C 125 MHz) NMR spectrometer. Chemical shifts are reported in δ values relative to internal Me₄Si.

2-Bromo-*N*-[2-(3,4-dimethoxyphenyl)ethyl]benzenepropanamide (4a). A mixture of 2-bromobenzenepropanoic acid (**3a**)⁹ (4.22 g, 18.4 mmol), homoveratrylamine (3.6 mL, 21 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (4.2 g, 22 mmol), 1-hydroxybenzotriazole (3.0 g, 22 mmol), and *N*-ethyldiisopropylamine (6.3 mL, 37 mmol) in DMF (75 mL) was stirred at rt for 19 h. The reaction mixture was poured into H₂O (200 mL) and extracted with AcOEt. The AcOEt extracts were washed successively with 10% aqueous citric acid, H₂O, and brine, dried over anhydrous Na₂SO₄, and concentrated *in vacuo*. Purification of the residual solid by flash chromatography [AcOEt–hexane (1 : 1.2)] gave **4a** (6.59 g, 91%) as a slightly yellow solid, mp 94–95 °C; MS (FAB) *m/z*: 392, 394 (M⁺+1); IR (ATR) ν , cm⁻¹: 3293 (NH), 1637 (CO) ¹H-NMR (CDCl₃) δ : 2.44 (2H, t, *J* = 7.7 Hz, COCH₂CH₂), 2.70 (2H, t, *J* = 6.9 Hz, NCH₂CH₂), 3.06 (2H, t, *J* = 7.7 Hz, COCH₂), 3.47 (2H, dt, *J* = 6.9, 5.9 Hz, NCH₂), 3.860 and 3.863 (3H each, s, two MeO's), 5.39 (1H, br, NH), 6.64 [1H, dd, *J* = 8.1, 2.0 Hz, C(6)-H], 6.67 [1H, d, *J* = 2.0 Hz, C(2)-H], 6.78 [1H, d, *J* = 8.1 Hz, C(5)-H], 7.07 [1H, ddd, *J* = 8.0, 7.0, 2.0 Hz, C(4')-H], 7.22 [1H, ddd, *J* = 7.8, 7.0, 1.2 Hz, C(5')-H], 7.26 [1H, dd, *J* = 7.8, 2.0 Hz, C(6')-H], 7.52 [1H, dd, *J* = 8.0, 1.2 Hz, C(3')-H];¹⁰ ¹³C-NMR (CDCl₃) δ : 32.2 (t), 35.3 (t), 36.5 (t), 40.8 (t), 55.89 (q), 55.95 (q), 111.3 (d), 111.8 (d), 120.7 (d), 124.3 (s), 127.7 (d), 128.1 (d), 130.8 (d), 131.4 (s), 132.8 (d), 140.1 (s), 147.7 (s), 149.0 (s), 171.8 (s).

2-Bromo-*N*-[2-(3,4-dimethoxyphenyl)ethyl]-4-methoxybenzenepropanamide (4b). Prepared from 2-bromo-4-methoxybenzenepropanoic acid (**3b**)¹¹ (1.17 g, 4.5 mmol) according to the procedure described for the preparation of **4a**. Purification by flash chromatography [AcOEt–hexane (2 : 1)] provided **4b** (1.81 g, 95%) as a pale yellow solid, mp 99–100 °C; MS (EI) *m/z*: 421, 423 (M⁺); IR (ATR) ν , cm⁻¹: 3305 (NH), 1638 (CO); ¹H-NMR (CDCl₃) δ : 2.40 (2H, t, *J* = 7.7 Hz, COCH₂CH₂), 2.70 (2H, t, *J* = 6.9 Hz, NCH₂CH₂), 2.99 (2H, t, *J* = 7.7 Hz, COCH₂), 3.46 (2H, dt, *J* = 6.9, 5.9 Hz, NCH₂), 3.77, 3.860, and 3.862 (3H each, s, three MeO's), 5.39 (1H, br, NH), 6.64 [1H, dd, *J* = 8.1, 1.8 Hz, C(6)-H], 6.68 [1H, d, *J* = 1.8 Hz, C(2)-H], 6.78 [1H, dd, *J* = 8.5, 2.6 Hz, C(5')-H], 6.79 [1H, d, *J* = 8.1 Hz, C(5)-H], 7.08 [1H, d, *J* = 2.6 Hz, C(3')-H], 7.15 [1H, d, *J* = 8.5 Hz, C(6')-H];¹⁰ ¹³C-NMR (CDCl₃) δ : 31.3 (t), 35.3 (t), 36.9 (t), 40.7 (t), 55.5 (q), 55.88 (q), 55.93 (q), 111.3 (d), 111.8 (d), 113.6 (d), 118.0 (d), 120.7 (d), 124.3 (s), 131.1 (d), 131.3 (s), 131.9 (s), 147.7 (s), 149.1 (s), 158.7 (s), 171.8 (s).

2-Bromo-*N*-[2-(3,4-dimethoxyphenyl)ethyl]-5-methoxybenzenepropanamide (4c). Synthesized from 2-bromo-5-methoxybenzenepropanoic acid (**3c**)¹² (3.32 g, 12.8 mmol) according to the procedure described for the preparation of **4a**. Purification by flash chromatography [AcOEt–hexane (2 : 1)] gave **4c** (5.09 g, 94%) as a pale yellow solid, mp 99–100 °C; MS (EI) *m/z*: 421, 423 (M⁺); IR (ATR) ν , cm⁻¹: 3296 (NH), 1635 (CO); ¹H-NMR (CDCl₃) δ : 2.43 (2H, t, *J* = 7.8 Hz, COCH₂CH₂), 2.71 (2H, t, *J* = 6.9 Hz, NCH₂CH₂), 3.02 (2H, t, *J* = 7.8 Hz, COCH₂), 3.47 (2H, dt, *J* = 6.9, 5.9 Hz, NCH₂), 3.76 (3H, s) and 3.86 (6H, s, three MeO's), 5.39 (1H, br, NH), 6.64 [1H, dd, *J* = 8.7, 3.1 Hz, C(4')-H], 6.65 [1H, dd, *J* = 8.1, 1.9

Hz, C(6)-H], 6.68 [1H, d, $J = 1.9$ Hz, C(2)-H], 6.79 [1H, d, $J = 8.1$ Hz, C(5)-H], 6.82 [1H, d, $J = 3.1$ Hz, C(6')-H], 7.39 [1H, d, $J = 8.7$ Hz, C(3')-H];¹⁰ ¹³C-NMR (CDCl₃) δ : 32.5 (t), 35.3 (t), 36.6 (t), 40.7 (t), 55.5 (q), 55.87 (q), 55.92 (q), 111.3 (d), 111.8 (d), 113.9 (d), 114.5 (s), 116.1 (d), 120.6 (d), 131.3 (s), 133.3 (d), 141.0 (s), 147.7 (s), 149.1 (s), 159.0 (s), 171.6 (s).

2-Bromo-*N*-[2-(3,4-dimethoxyphenyl)ethyl]-4-fluorobenzenepropanamide (4d). Prepared from 2-bromo-4-fluorobenzenepropanoic acid (**3d**)¹³ (4.00 g, 16.2 mmol) according to the method described for the preparation of **4a**. Purification by flash chromatography [AcOEt–hexane (1 : 2)] furnished **4d** (5.08 g, 76%) as a pale yellow solid, mp 110–111.5 °C; MS (EI) m/z : 409, 411 (M^+); IR (ATR) ν , cm⁻¹: 3307 (NH), 1639 (CO); ¹H-NMR (CDCl₃) δ : 2.41 (2H, t, $J = 7.6$ Hz, COCH₂CH₂), 2.71 (2H, t, $J = 6.9$ Hz, NCH₂CH₂), 3.03 (2H, t, $J = 7.6$ Hz, COCH₂), 3.47 (2H, dt, $J = 6.9, 6.0$ Hz, NCH₂), 3.86 and 3.87 (3H each, s, two MeO's), 5.40 (1H, br, NH), 6.64 [1H, dd, $J = 8.1, 1.9$ Hz, C(6)-H], 6.67 [1H, d, $J = 1.9$ Hz, C(2)-H], 6.79 [1H, d, $J = 8.1$ Hz, C(5)-H], 6.95 [1H, ddd, $J = 8.5, 8.2, 2.6$ Hz, C(5')-H], 7.23 [1H, dd, $J = 8.5, 6.1$ Hz, C(6')-H], 7.27 [1H, dd, $J = 8.2, 2.6$ Hz, C(3')-H];¹⁰ ¹³C-NMR (CDCl₃) δ : 31.3 (t), 35.2 (t), 36.5 (t), 40.7 (t), 55.86 (q), 55.90 (q), 111.2 (d), 111.7 (d), 114.7 (d), 119.9 (d), 120.6 (d), 123.9 (s), 131.2 (d), 131.5 (s), 135.9 (s), 147.7 (s), 149.0 (s), 161.0 (s), 171.5 (s).

2-Bromo-*N*-[2-(3,4-dimethoxyphenyl)ethyl]-5-chlorobenzenepropanamide (4e). Synthesized from 2-bromo-5-chlorobenzenepropanoic acid (**3e**)¹⁴ (5.50 g, 20.9 mmol) according to the procedure described for the preparation of **4a**. Purification by flash chromatography [AcOEt–hexane (1 : 1)] gave **4e** (8.70 g, 98%) as a colorless solid, mp 107–108 °C; MS (EI) m/z : 425 (M^+); IR (ATR) ν , cm⁻¹: 3301 (NH), 1632 (CO); ¹H-NMR (CDCl₃) δ : 2.42 (2H, t, $J = 7.7$ Hz, COCH₂CH₂), 2.72 (2H, t, $J = 7.0$ Hz, NCH₂CH₂), 3.03 (2H, t, $J = 7.7$ Hz, COCH₂), 3.48 (2H, dt, $J = 7.0, 5.9$ Hz, NCH₂), 3.86 (6H, s, two MeO's), 5.40 (1H, br, NH), 6.65 [1H, dd, $J = 8.0, 2.0$ Hz, C(6)-H], 6.68 [1H, d, $J = 2.0$ Hz, C(2)-H], 6.79 [1H, d, $J = 8.0$ Hz, C(5)-H], 7.06 [1H, dd, $J = 8.5, 2.6$ Hz, C(4')-H], 7.25 [1H, d, $J = 2.6$ Hz, C(6')-H], 7.44 [1H, d, $J = 8.5$ Hz, C(3')-H];¹⁰ ¹³C-NMR (CDCl₃) δ : 32.0 (t), 35.2 (t), 36.1 (t), 40.7 (t), 55.87 (q), 55.92 (q), 111.3 (d), 111.7 (d), 120.6 (d), 122.1 (s), 128.1 (d), 130.6 (d), 131.2 (s), 133.4 (s), 133.8 (d), 141.8 (s), 147.7 (s), 149.1 (s), 171.2 (s).

2-Bromo-*N*-[2-(3,4-dimethoxyphenyl)ethyl]-4,5-dimethoxybenzenepropanamide (4f). Obtained from 2-bromo-4,5-dimethoxybenzenepropanoic acid (**3f**)¹⁵ (6.45 g, 22.3 mmol) according to the method described for the preparation of **4a**. Purification by flash chromatography [AcOEt–hexane (2 : 1)] afforded **4f** (9.79 g, 97%) as a colorless solid, mp 124–125 °C (lit.^{15a,b} mp 123–125 °C); MS (FAB) m/z : 452, 454 ($M^+ + 1$); IR (ATR) ν , cm⁻¹: 3307 (NH), 1641 (CO); ¹H-NMR (CDCl₃) δ : 2.41 (2H, t, $J = 7.7$ Hz, COCH₂CH₂), 2.71 (2H, t, $J = 6.9$ Hz, NCH₂CH₂), 2.99 (2H, t, $J = 7.7$ Hz, COCH₂), 3.47 (2H, dt, $J = 6.9, 5.9$ Hz, NCH₂), 3.84 (3H, s), 3.85 (3H, s), and 3.86 (6H, s, four MeO's), 5.39 (1H, br, NH), 6.65 [1H, dd,

$J = 8.0, 1.8$ Hz, C(6)-H], 6.67 [1H, d, $J = 1.8$ Hz, C(2)-H], 6.787 [1H, s, C(6')-H], 6.788 [1H, d, $J = 8.0$ Hz, C(5)-H], 6.98 [1H, s, C(3')-H];¹⁰ ¹³C-NMR (CDCl₃) δ : 31.9 (t), 35.3 (t), 36.9 (t), 40.8 (t), 55.8 (q), 55.9 (q), 56.0 (q), 56.1 (q), 111.3 (d), 111.8 (d), 113.3 (d), 113.8 (s), 115.5 (d), 120.6 (d), 131.4 (s), 132.1 (s), 147.6 (s), 148.1 (s), 148.4 (s), 149.0 (s), 171.9 (s).

6-Bromo-*N*-[2-(3,4-dimethoxyphenyl)ethyl]-1,3-benzodioxole-5-propanamide (4g). Synthesized from 6-bromo-1,3-benzodioxole-5-propanoic acid (**3g**)¹⁶ (7.72 g, 28.3 mmol) according to the method described for the preparation of **4a**. Purification by flash chromatography [AcOEt–hexane (2 : 1)] furnished **4g** (11.2 g, 91%) as a colorless solid, mp 140–141 °C; MS (EI) m/z : 435, 437 (M⁺); IR (ATR) ν , cm⁻¹: 3268 (NH), 1634 (CO); ¹H-NMR (CDCl₃) δ : 2.38 (2H, t, $J = 7.7$ Hz, COCH₂CH₂), 2.72 (2H, t, $J = 6.9$ Hz, NCH₂CH₂), 2.96 (2H, t, $J = 7.7$ Hz, COCH₂), 3.48 (2H, dt, $J = 6.9, 5.9$ Hz, NCH₂), 3.87 (6H, s, two MeO's), 5.39 (1H, br, NH), 5.94 (2H, s, OCH₂O), 6.66 [1H, dd, $J = 8.1, 1.9$ Hz, C(6)-H], 6.69 [1H, d, $J = 1.9$ Hz, C(2)-H], 6.75 [1H, s, C(6')-H], 6.79 [1H, d, $J = 8.1$ Hz, C(5)-H], 6.97 [1H, s, C(3')-H];¹⁰ ¹³C-NMR (CDCl₃) δ : 32.1 (t), 35.3 (t), 36.7 (t), 40.8 (t), 55.89 (q), 55.94 (q), 101.7 (t), 110.3 (d), 111.3 (d), 111.8 (d), 112.7 (d), 114.2 (s), 120.7 (d), 131.4 (s), 133.1 (s), 147.0 (s), 147.4 (s), 147.7 (s), 149.1 (s), 171.7 (s).

1-[2-(3,4-Dimethoxyphenyl)ethyl]-3,4-dihydro-2(1H)-quinolinone (5a). A stirred solution of **4a** (6.01 g, 15.3 mmol), tris(dibenzylideneacetone)dipalladium (1.33 g, 1.5 mmol), tri-*t*-butylphosphonium tetrafluoroborate (1.05 g, 3.6 mmol), *N,N*-dicyclohexylmethylamine (4.2 mL, 20 mmol) in DMF (46 mL) was heated in an atmosphere of Ar at 100 °C for 137 h. The reaction mixture was poured into H₂O (100 mL) and extracted with AcOEt. The AcOEt extracts were washed successively with 1 M aqueous HCl, H₂O and brine, dried over anhydrous Na₂SO₄, and concentrated *in vacuo* to leave a brown oil. Purification by flash chromatography [AcOEt–hexane (2 : 3)] gave **5a** (3.66 g, 77%) as a slightly yellow solid, mp 62–63 °C (lit.³ mp 64.5–65.5 °C). ¹H-NMR and IR spectral data for this sample were in agreement with those reported in the literature.³

1-[2-(3,4-Dimethoxyphenyl)ethyl]-3,4-dihydro-7-methoxy-2(1H)-quinolinone (5b). A mixture of **4b** (3.61 g, 8.5 mmol), tris(dibenzylideneacetone)dipalladium (381 mg, 0.42 mmol), tri-*t*-butylphosphonium tetrafluoroborate (743 mg, 2.6 mmol), *N,N*-dicyclohexylmethylamine (2.2 mL, 10 mmol), and DMF (50 mL) was stirred in an atmosphere of Ar at 110 °C for 92 h. The reaction mixture was treated with 1 M aqueous HCl (100 mL) and extracted with AcOEt. The AcOEt extracts were washed successively with H₂O and brine, dried over anhydrous Na₂SO₄, and concentrated *in vacuo*. Purification of the residual oil by flash chromatography [AcOEt–hexane (1 : 1)] provided **5b** (2.29 g, 78%) as a pale yellow solid, mp 90–91 °C; MS (EI) m/z : 341 (M⁺); IR (ATR) ν : 1662 cm⁻¹ (CO); ¹H-NMR (CDCl₃) δ : 2.60 and 2.76 [2H each, t, $J = 7.3$ Hz, C(3)-H's, C(4)-H's], 2.89 (2H, t, $J = 7.9$ Hz, NCH₂CH₂), 3.81 (3H, s) and 3.86 (6H, s, three MeO's), 4.12 (2H, t, $J = 7.9$ Hz, NCH₂), 6.55 [1H, dd, $J = 8.2, 2.4$ Hz, C(6)-H], 6.61 [1H, d, $J = 2.4$

Hz, C(8)-H], 6.75–6.82 [3H, m, (MeO)₂C₆H₃], 7.07 [1H, d, *J* = 8.2 Hz, C(5)-H]; ¹³C-NMR (CDCl₃) δ: 24.7 (t), 32.3 (t), 33.0 (t), 43.8 (t), 55.4 (q), 55.87 (q), 55.92 (q), 102.7 (d), 106.5 (d), 111.3 (d), 112.1 (d), 119.0 (s), 120.7 (d), 128.5 (d), 131.2 (s), 140.5 (s), 147.7 (s), 148.9 (s), 159.2 (s), 170.3 (s).

1-[2-(3,4-Dimethoxyphenyl)ethyl]-3,4-dihydro-6-methoxy-2(1H)-quinolinone (5c). Prepared from **4c** (7.53 g, 17.8 mmol) according to the procedure described for the preparation of **5b**. Purification by flash chromatography [AcOEt–hexane (1 : 1)] afforded **5c** (3.09 g, 51%) as a pale yellow solid, mp 72–73 °C; MS (EI) *m/z*: 341 (M⁺); IR (ATR) *v*: 1660 cm⁻¹ (CO); ¹H-NMR (CDCl₃) δ: 2.60 and 2.78 [2H each, t, *J* = 7.3 Hz, C(3)-H's, C(4)-H's], 2.88 (2H, t, *J* = 7.8 Hz, NCH₂CH₂), 3.80 (3H, s) and 3.86 (6H, s, three MeO's), 4.13 (2H, t, *J* = 7.8 Hz, NCH₂), 6.73–6.81 [5H, m, (MeO)₂C₆H₃, C(5)-H, C(7)-H], 6.95 [1H, d, *J* = 8.8 Hz, C(8)-H]; ¹³C-NMR (CDCl₃) δ: 25.8 (t), 31.9 (t), 33.0 (t), 43.6 (t), 55.6 (q), 55.89 (q), 55.92 (q), 111.2 (d), 112.0 (d), 112.1 (d), 114.0 (d), 115.2 (d), 120.7 (d), 128.4 (s), 131.2 (s), 133.0 (s), 147.6 (s), 148.9 (s), 155.2 (s), 169.8 (s).

1-[2-(3,4-Dimethoxyphenyl)ethyl]-3,4-dihydro-7-fluoro-2(1H)-quinolinone (5d). Synthesized from **4d** (4.70 g, 11.5 mmol) according to the method described for the preparation of **5b**. Purification by flash chromatography [AcOEt–hexane (1 : 1)] afforded **5d** (1.86 g, 49%) as a pale yellow solid, mp 107–108 °C, MS (EI) *m/z*: 329 (M⁺); IR (ATR) *v*: 1680 cm⁻¹ (CO); ¹H-NMR (CDCl₃) δ: 2.61 and 2.79 [2H each, t, *J* = 7.3 Hz, C(3)-H's, C(4)-H's], 2.88 (2H, t, *J* = 7.9 Hz, NCH₂CH₂), 3.863 and 3.865 (3H each, s, two MeO's), 4.11 (2H, t, *J* = 7.9 Hz, NCH₂), 6.71 [1H, ddd, *J* = 8.2, 8.2, 2.4 Hz, C(6)-H], 6.74–6.82 [4H, m, (MeO)₂C₆H₃, C(8)-H], 7.10 [1H, dd, *J* = 8.2, 6.4 Hz, C(5)-H]; ¹³C-NMR (CDCl₃) δ: 24.9 (t), 31.9 (t), 32.9 (t), 43.7 (t), 55.87 (q), 55.91 (q), 102.9 (d), 109.0 (d), 111.2 (d), 112.0 (d), 120.7 (d), 122.2 (s), 128.9 (d), 130.8 (s), 140.8 (s), 147.7 (s), 148.9 (s), 162.2 (s), 170.0 (s).

1-[2-(3,4-Dimethoxyphenyl)ethyl]-3,4-dihydro-6-chloro-2(1H)-quinolinone (5e). Obtained from **4e** (8.50 g, 19.9 mmol) according to the procedure described for the preparation of **5b**. Purification by flash chromatography [AcOEt–hexane (1 : 1)] gave **5e** (3.98 g, 58%) as a pale yellow solid, mp 96–97 °C, MS (EI) *m/z*: 345, 347 (M⁺); IR (ATR) *v*: 1669 cm⁻¹ (CO); ¹H-NMR (CDCl₃) δ: 2.60 and 2.78 [2H each, t, *J* = 7.3 Hz, C(3)-H's, C(4)-H's], 2.87 (2H, t, *J* = 7.8 Hz, NCH₂CH₂), 3.855 and 3.859 (3H each, s, two MeO's), 4.13 (2H, t, *J* = 7.8 Hz, NCH₂), 6.72–6.80 [3H, m, (MeO)₂C₆H₃], 6.94 [1H, d, *J* = 8.7 Hz, C(8)-H], 7.14 [1H, d, *J* = 2.4 Hz, C(5)-H], 7.22 [1H, dd, *J* = 8.7, 2.4 Hz, C(7)-H]; ¹³C-NMR (CDCl₃) δ: 25.3 (t), 31.6 (t), 32.9 (t), 43.5 (t), 55.88 (q), 55.90 (q), 111.2 (d), 112.0 (d), 116.1 (d), 120.7 (d), 127.3 (d), 127.9 (s), 128.0 (d), 128.6 (s), 130.8 (s), 138.1 (s), 147.7 (s), 148.9 (s), 169.7 (s).

1-[2-(3,4-Dimethoxyphenyl)ethyl]-3,4-dihydro-6,7-dimethoxy-2(1H)-quinolinone (5f). Prepared from **4f** (4.52 g, 10.0 mmol) according to the procedure described for the preparation of **5b**. Purification by flash chromatography [AcOEt–hexane (1 : 1)] afforded **5f** (1.37 g, 37%) as a pale yellow solid, mp 132–133 °C, MS (EI) *m/z*: 371 (M⁺); IR (ATR) *v*: 1642 cm⁻¹ (CO); ¹H-NMR (CDCl₃) δ: 2.60 and 2.75

[2H each, t, $J = 7.3$ Hz, C(3)-H's, C(4)-H's], 2.91 (2H, t, $J = 7.6$ Hz, NCH₂CH₂), 3.84 (6H, s), 3.85 (3H, s), and 3.87 (3H, s, four MeO's), 4.13 (2H, t, $J = 7.6$ Hz, NCH₂), 6.53 and 6.69 [1H each, s, C(5)-H, C(8)-H], 6.73–6.80 [3H, m, (MeO)₂C₆H₃]; ¹³C-NMR (CDCl₃) δ : 25.2 (t), 32.3 (t), 33.3 (t), 44.0 (t), 55.8 (q), 55.9 (q), 56.29 (q), 56.31 (q), 100.9 (d), 111.3 (d), 111.7 (s), 112.1 (d), 118.7 (s), 120.7 (d), 131.3 (s), 132.9 (s), 144.5 (s), 147.7 (s), 148.0 (s), 149.0 (s), 169.9 (s).

7,8-Dihydro-5-[2-(3,4-dimethoxyphenyl)ethyl]-1,3-dioxolo[4,5-g]quinolin-6(5H)-one (5g). Prepared from **4g** (3.55 g, 8.1 mmol) according to the procedure described for the preparation of **5b**. Purification by flash chromatography [AcOEt–hexane (3 : 1)] provided **5g** (1.62 g, 56%) as a pale yellow solid, mp 108–109 °C; MS (EI) m/z : 355 (M⁺); IR (ATR) ν : 1663 cm⁻¹ (CO); ¹H-NMR (CDCl₃) δ : 2.56 and 2.69 [2H each, t, $J = 7.2$ Hz, C(3)-H's, C(4)-H's], 2.87 (2H, t, $J = 7.9$ Hz, NCH₂CH₂), 3.86 and 3.87 (3H each, s, two MeO's), 4.09 (2H, t, $J = 7.9$ Hz, NCH₂), 5.96 (2H, s, OCH₂O), 6.63 and 6.65 [1H each, s, C(5)-H, C(8)-H], 6.74–6.81 [3H, m, (MeO)₂C₆H₃]; ¹³C-NMR (CDCl₃) δ : 25.5 (t), 32.2 (t), 33.1 (t), 43.9 (t), 55.89 (q), 55.92 (q), 97.8 (d), 101.3 (t), 108.2 (d), 111.3 (d), 112.1 (d), 119.8 (s), 120.8 (d), 131.0 (s), 133.7 (s), 142.8 (s), 146.9 (s), 147.7 (s), 148.9 (s), 170.0 (s).

1-[2-(3,4-Dimethoxyphenyl)ethyl]-7-methoxy-2(1H)-quinolinone (6b). A solution of **5b** (171 mg, 0.5 mmol) and DDQ (136 mg, 0.6 mmol) in dioxane (5 mL) was heated with stirring at 80 °C for 2 h. After the mixture had been concentrated *in vacuo*, the residue was partitioned between CHCl₃ and 5% aqueous K₂CO₃. The CHCl₃ extracts were washed successively with H₂O and brine, dried over anhydrous MgSO₄, and concentrated *in vacuo*. The residual oil was purified by flash chromatography [AcOEt–hexane (2 : 1)] to give **6b** (134 mg, 79%) as a pale yellow solid, mp 125–126 °C; MS (FAB) m/z : 340 (M⁺+1); IR (ATR) ν : 1646 cm⁻¹ (CO); ¹H-NMR (CDCl₃) δ : 2.98 (2H, t, $J = 8.1$ Hz, ArCH₂), 3.86, 3.87, and 3.89 (3H each, s, three MeO's), 4.44 (2H, t, $J = 8.1$ Hz, NCH₂), 6.57 [1H, d, $J = 9.4$ Hz, C(3)-H], 6.81–6.88 [5H, m, (MeO)₂C₆H₃, C(6)-H, C(8)-H], 7.48 [1H, d, $J = 8.4$ Hz, C(5)-H], 7.62 [1H, d, $J = 9.4$ Hz, C(4)-H]; ¹³C-NMR (CDCl₃) δ : 33.1 (t), 44.2 (t), 55.5 (q), 55.9 (q), 56.0 (q), 98.8 (d), 109.4 (d), 111.4 (d), 112.1 (d), 115.2 (s), 118.6 (d), 120.6 (d), 130.3 (d), 131.1 (s), 139.0 (d), 140.9 (s), 147.8 (s), 149.1 (s), 161.8 (s), 162.4 (s).

1-[2-(3,4-Dimethoxyphenyl)ethyl]-6,7-dimethoxy-2(1H)-quinolinone (6f). A mixture of **5f** (371 mg, 1.0 mmol), DDQ (318 mg, 1.4 mmol), and dioxane (10 mL) was stirred at 80 °C for 30 min. The reaction mixture was then worked up as described above for the preparation of **6b**. Purification by flash chromatography [AcOEt–hexane (10 : 1)] afforded **6f** (299 mg, 81%) as a pale brown solid, mp 147–148 °C; MS (FAB) m/z : 370 (M⁺+1); IR (ATR) ν : 1645 cm⁻¹ (CO); ¹H-NMR (CDCl₃) δ : 3.02 (2H, t, $J = 7.8$ Hz, ArCH₂), 3.82, 3.86, 3.928, and 3.934 (3H each, s, four MeO's), 4.48 (2H, t, $J = 7.8$ Hz, NCH₂), 6.62 [1H, d, $J = 9.4$ Hz, C(3)-H], 6.72 and 6.95 [1H each, s, C(5)-H, C(8)-H], 6.78–6.84 [3H, m, (MeO)₂C₆H₃], 7.59 [1H, d, $J = 9.4$ Hz, C(4)-H]; ¹³C-NMR (CDCl₃) δ : 33.4 (t), 44.5 (t), 55.8 (q), 55.9 (q),

56.0 (q), 56.2 (q), 97.3 (d), 109.4 (d), 111.4 (d), 112.1 (d), 114.2 (s), 119.1 (d), 120.5 (d), 131.2 (s), 134.9 (s), 138.5 (d), 145.0 (s), 147.9 (s), 149.1 (s), 152.0 (s), 162.0 (s).

5-[2-(3,4-Dimethoxyphenyl)ethyl]-1,3-dioxolo[4,5-g]quinolin-6(5H)-one (6g). Prepared from **5g** (1.13 g, 3.2 mmol) according to the method described for the preparation of **6f**. Purification by flash chromatography [AcOEt–hexane (5 : 1)] gave **6g** (834 mg, 74%) as a slightly yellow solid, mp 137–139 °C; MS (FAB) m/z : 354 ($M^+ + 1$); IR (ATR) ν : 1650 cm^{-1} (CO); $^1\text{H-NMR}$ (CDCl_3) δ : 2.96 (2H, t, $J = 8.2$ Hz, ArCH_2), 3.877 and 3.879 (3H each, s, two MeO's), 4.42 (2H, t, $J = 8.2$ Hz, NCH_2), 6.07 (2H, s, OCH_2O), 6.60 [1H, d, $J = 9.5$ Hz, C(3)-H], 6.83–6.89 [3H, m, $(\text{MeO})_2\text{C}_6\text{H}_3$], 6.88 and 6.94 [1H each, s, C(5)-H, C(8)-H], 7.55 [1H, d, $J = 9.5$ Hz, C(4)-H]; $^{13}\text{C-NMR}$ (CDCl_3) δ : 33.2 (t), 44.7 (t), 55.92 (q), 55.94 (q), 95.0 (d), 101.9 (t), 106.5 (d), 111.4 (d), 112.1 (d), 115.4 (s), 119.0 (d), 120.7 (d), 130.9 (s), 136.3 (s), 138.7 (d), 143.3 (s), 147.9 (s), 149.1 (s), 151.0 (s), 161.9 (s).

6,7-Dihydro-9,10-dimethoxydibenzo[*a,f*]quinolizinium Triiodide (2a: X = I₃). A mixture of **5a** (311 mg, 1.0 mmol) and POCl_3 (1 mL, 11 mmol) in toluene (5 mL) was heated under reflux with stirring for 6 h. The solvent and excess POCl_3 were distilled off *in vacuo* to leave an orange solid, which was then triturated with Et_2O . The insoluble material was collected by filtration and dissolved in hot H_2O (15 mL). The solution was then cooled and treated with 0.5 M aqueous I_2/KI (4 mL) at 0 °C for 30 min. The precipitate that resulted was collected by filtration and dried to afford **2a** (549 mg, 87%) as a dark brown solid. Recrystallization from MeOH gave an orange solid, mp 190–191 °C; $^1\text{H-NMR}$ ($\text{DMSO-}d_6$) δ : 3.33 [2H, t, $J = 7.1$ Hz, C(7)-H's], 3.94 and 3.95 (3H each, s, two MeO's), 5.09 [2H, t, $J = 7.1$ Hz, C(6)-H's], 7.26 [1H, s, C(8)-H], 7.82 [1H, s, C(11)-H], 7.94 [1H, dd, $J = 8.1, 7.1$ Hz, C(2)-H], 8.20 [1H, ddd, $J = 9.0, 7.1, 1.5$ Hz, C(3)-H], 8.38 [1H, dd, $J = 8.1, 1.5$ Hz, C(1)-H], 8.64 [1H, d, $J = 9.0$ Hz, C(4)-H], 8.76 [1H, d, $J = 9.0$ Hz, C(12)-H], 9.12 [1H, d, $J = 9.0$ Hz, C(13)-H];¹⁷ $^{13}\text{C-NMR}$ ($\text{DMSO-}d_6$) δ : 24.0 (t), 45.5 (t), 55.0 (q), 55.1 (q), 109.7 (d), 110.2 (d), 117.1 (d), 117.6 (s), 119.0 (d), 126.3 (s), 127.4 (d), 128.9 (d), 130.7 (s), 133.5 (d), 137.3 (s), 143.6 (d), 147.3 (s), 150.2 (s), 153.0 (s). *Anal.* Calcd for $\text{C}_{19}\text{H}_{18}\text{I}_3\text{NO}_2$: C, 33.91; H, 2.70; N, 2.08. Found: C, 33.70; H, 2.73; N, 2.04.

6,7-Dihydro-3,9,10-trimethoxydibenzo[*a,f*]quinolizinium Chloride (2b: X = Cl). A stirred mixture of **6b** (170 mg, 0.5 mmol) and POCl_3 (1 mL, 11 mmol) was heated under reflux for 28 h. After cooling, the reaction mixture was treated with cold H_2O , and the insoluble material was collected by filtration and dried to give **2b** (82.1 mg, 46%) as a yellow solid, mp 294–295 °C; $^1\text{H-NMR}$ ($\text{DMSO-}d_6$) δ : 3.31 [2H, t, $J = 7.0$ Hz, C(7)-H's], 3.937, 3.943, and 4.11 (3H each, s, three MeO's), 5.03 [2H, t, $J = 7.0$ Hz, C(6)-H's], 7.25 [1H, s, C(8)-H], 7.60 [1H, dd, $J = 9.0, 1.9$ Hz, C(2)-H], 7.79 [1H, s, C(11)-H], 7.86 [1H, d, $J = 1.9$ Hz, C(4)-H], 8.31 [1H, d, $J = 9.0$ Hz, C(1)-H], 8.58 [1H, d, $J = 8.8$ Hz, C(12)-H], 9.02 [1H, d, $J = 8.8$ Hz, C(13)-H]; $^{13}\text{C-NMR}$ ($\text{DMSO-}d_6$) δ : 25.3 (t), 46.6 (t), 56.1 (q), 56.2 (q), 56.7 (q), 99.1 (d), 110.9 (d), 111.2

(d), 117.3 (d), 119.1 (s), 120.3 (d), 123.1 (s), 131.5 (s), 131.9 (d), 141.0 (s), 144.3 (d), 148.6 (s), 150.8 (s), 153.9 (s), 164.5 (s).

6,7-Dihydro-2,9,10-trimethoxydibenzo[*a,f*]quinolizinium Triiodide (2c: X = I₃). Cyclization of **5c** (341 mg, 1.1 mmol) was carried out as described above for the preparation of **2a**, giving the iminium salt (360 mg) as an orange solid. To a solution of the solid in DMSO (1 mL) was added 0.5 M aqueous I₂/KI (2 mL), and the mixture was stirred at 0 °C for 30 min. After addition of H₂O (10 mL), the precipitate that resulted was collected by filtration and dried to afford **2c** (620 mg, 88%) as a dark brown solid, mp 274–275 °C; ¹H-NMR (DMSO-*d*₆) δ: 3.31 [2H, t, *J* = 7.0 Hz, C(7)-H's], 3.936, 3.943, and 4.01 (3H each, s, three MeO's), 5.06 [2H, t, *J* = 7.0 Hz, C(6)-H's], 7.22 [1H, s, C(8)-H], 7.79 [1H, s, C(11)-H], 7.81 [1H, dd, *J* = 9.5, 2.9 Hz, C(3)-H], 7.84 [1H, d, *J* = 2.9 Hz, C(1)-H], 8.56 [1H, d, *J* = 9.5 Hz, C(4)-H], 8.70 [1H, d, *J* = 9.1 Hz, C(12)-H], 8.98 [1H, d, *J* = 9.1 Hz, C(13)-H]; ¹³C-NMR (DMSO-*d*₆) δ: 24.0 (t), 45.8 (t), 54.88 (q), 54.92 (q), 55.0 (q), 107.4 (d), 109.8 (d), 110.1 (d), 117.7 (s), 118.9 (d), 119.2 (d), 124.7 (d), 128.3 (s), 130.0 (s), 132.7 (s), 142.2 (d), 147.4 (s), 147.8 (s), 152.7 (s), 157.2 (s).

3-Fluoro-6,7-dihydro-9,10-dimethoxydibenzo[*a,f*]quinolizinium Triiodide (2d: X = I₃). Cyclization of **5d** (160 mg, 0.49 mmol) and subsequent oxidation were performed as described for the synthesis of **2c** to afford **2d** (270 mg, 80%) as a dark brown solid, mp 200–201 °C; ¹H-NMR (DMSO-*d*₆) δ: 3.33 [2H, t, *J* = 7.1 Hz, C(7)-H's], 3.95 (6H, s, two MeO's), 5.01 [2H, t, *J* = 7.1 Hz, C(6)-H's], 7.24 [1H, s, C(8)-H], 7.82 [1H, s, C(11)-H], 7.90 [1H, ddd, *J* = 9.0, 8.2, 2.0 Hz, C(2)-H], 8.49 [1H, dd, *J* = 9.0, 6.3 Hz, C(1)-H], 8.56 [1H, dd, *J* = 11.8, 2.0 Hz, C(4)-H], 8.73 [1H, d, *J* = 9.0 Hz, C(12)-H], 9.12 [1H, d, *J* = 9.0 Hz, C(13)-H]; ¹³C-NMR (DMSO-*d*₆) δ: 23.9 (t), 46.0 (t), 55.0 (q), 55.1 (q), 103.6 (d), 109.8 (d), 110.5 (d), 117.2 (d), 117.5 (s), 118.4 (d), 123.7 (s), 131.0 (s), 132.1 (d), 139.0 (s), 143.5 (d), 147.5 (s), 151.0 (s), 153.4 (s), 164.0 (s). *Anal.* Calcd for C₁₉H₁₇FI₃NO₂: C, 33.02; H, 2.48; N, 2.03. Found: C, 33.20; H, 2.40; N, 2.08.

2-Chloro-6,7-dihydro-9,10-dimethoxydibenzo[*a,f*]quinolizinium Triiodide (2e: X = I₃). Prepared from **5e** (170 mg, 0.49 mmol) according to the procedure described for the preparation of **2c** to give **2e** (225 mg, 77%) as a dark brown solid, mp 287–288 °C; ¹H-NMR (DMSO-*d*₆) δ: 3.34 [2H, t, *J* = 7.1 Hz, C(7)-H's], 3.951 and 3.954 (3H each, s, two MeO's), 5.08 [2H, t, *J* = 7.1 Hz, C(6)-H's], 7.26 [1H, s, C(8)-H], 7.82 [1H, s, C(11)-H], 8.21 [1H, dd, *J* = 9.5, 2.5 Hz, C(3)-H], 8.53 [1H, d, *J* = 2.5 Hz, C(1)-H], 8.66 [1H, d, *J* = 9.5 Hz, C(4)-H], 8.81 [1H, d, *J* = 9.1 Hz, C(12)-H], 9.04 [1H, d, *J* = 9.1 Hz, C(13)-H]; ¹³C-NMR (DMSO-*d*₆) δ: 23.9 (t), 46.0 (t), 55.0 (q), 55.1 (q), 109.9 (d), 110.5 (d), 117.4 (s), 119.6 (d), 120.3 (d), 127.3 (s), 127.4 (d), 131.0 (s), 131.7 (s), 133.2 (d), 136.1 (s), 142.6 (d), 147.5 (s), 150.6 (s), 153.5 (s). *Anal.* Calcd for C₁₉H₁₇ClI₃NO₂: C, 32.26; H, 2.42; N, 1.98. Found: C, 32.25; H, 2.61; N, 1.92.

6,7-Dihydro-2,3,9,10-tetramethoxydibenzo[*a,f*]quinolizinium Triiodide (2f: X = I₃). Synthesized from **5f** (130 mg, 0.35 mmol) according to the method described for the preparation of **2c** to furnish **2f** (248 mg,

97%) as a brown solid, mp 214–216 °C; ¹H-NMR (DMSO-*d*₆) δ: 3.30 [2H, t, *J* = 6.9 Hz, C(7)-H's], 3.927, 3.933, 4.01, and 4.14 (3H each, s, four MeO's), 5.04 [2H, t, *J* = 6.9 Hz, C(6)-H's], 7.22 [1H, s, C(8)-H], 7.74, 7.80, and 7.82 [1H each, s, C(1)-H, C(4)-H, C(11)-H], 8.53 [1H, d, *J* = 8.8 Hz, C(12)-H], 8.87 [1H, d, *J* = 8.8 Hz, C(13)-H]; ¹³C-NMR (DMSO-*d*₆) δ: 24.2 (t), 45.8 (t), 54.8 (q), 55.0 (q), 55.1 (q), 55.9 (q), 97.7 (d), 106.7 (d), 109.6 (d), 109.7 (d), 116.4 (d), 118.0 (s), 122.9 (s), 129.3 (s), 134.8 (s), 141.1 (d), 146.7 (s), 147.4 (s), 148.9 (s), 152.2 (s), 154.8 (s). *Anal.* Calcd for C₂₁H₂₂I₃NO₄: C, 34.41; H, 3.02; N, 1.91. Found: C, 34.71; H, 3.08; N, 2.03.

13,14-Dihydro-2,3-dimethoxybenzo[*a*][1,3]benzodioxolo[5,6-*f*]quinolizinium Triiodide (2g: X = I₃).

Prepared from **5g** (180 mg, 0.51 mmol) according to the procedure described for the preparation of **2c** to provide **2g** (350 mg, 96%) as a brown solid, mp 226–227 °C; ¹H-NMR (DMSO-*d*₆) δ: 3.27 [2H, t, *J* = 6.9 Hz, C(7)-H's], 3.92 and 3.93 (3H each, s, two MeO's), 4.94 [2H, t, *J* = 6.9 Hz, C(6)-H's], 6.44 (2H, s, OCH₂O), 7.19 [1H, s, C(8)-H], 7.72, 7.74, and 8.16 [1H each, s, C(1)-H, C(4)-H, C(11)-H], 8.52 [1H, d, *J* = 8.9 Hz, C(12)-H], 8.83 [1H, d, *J* = 8.9 Hz, C(13)-H]; ¹³C-NMR (DMSO-*d*₆) δ: 24.1 (t), 46.4 (t), 54.8 (q), 55.0 (q), 95.6 (d), 102.9 (t), 103.5 (d), 109.67 (d), 109.72 (d), 116.7 (d), 117.8 (s), 124.5 (s), 129.4 (s), 136.7 (s), 141.7 (d), 147.2 (s), 147.4 (s), 147.5 (s), 152.3 (s), 153.9 (s). *Anal.* Calcd for C₂₀H₁₈I₃NO₄: C, 33.50; H, 2.53; N, 1.95. Found: C, 33.69; H, 2.55; N, 1.92.

ACKNOWLEDGEMENTS

The authors are grateful to Ms. Natsuki Tsuchiya and Ms. Marika Osada of Yokohama University of Pharmacy for technical assistance. We also thank A Rabbit Science Japan Co. Ltd. for elemental analyses.

REFERENCES AND NOTES

- (a) S. Sugasawa, *Yakugaku Zasshi*, 1937, **57**, 1028; (b) S. Sugasawa and K. Kakemi, *Proc. Imp. Acad. Tokyo*, 1938, **14**, 214; (c) S. Sugasawa and N. Sugimoto, *Proc. Imp. Acad. Tokyo*, 1939, **15**, 49; (d) K. Kakemi, *Yakugaku Zasshi*, 1940, **60**, 2; (e) S. Sugasawa and N. Sugimoto, *Proc. Imp. Acad. Tokyo*, 1942, **18**, 658; (f) S. Akahoshi, *Yakugaku Zasshi*, 1952, **72**, 1277; (g) D. W. Brown, S. F. Dyke, M. Sainsbury, and W. G. D. Lugton, *Tetrahedron*, 1970, **26**, 4985; (h) D. Tourwé and G. Van Binst, *Bull. Soc. Chim. Belg.*, 1976, **85**, 11.
- (a) T. Kametani, T. Terui, and K. Fukumoto, *Yakugaku Zasshi*, 1968, **88**, 1388; (b) L. Amoros-Marin and C. K. Bradsher, *J. Heterocycl. Chem.*, 1970, **7**, 1421; (c) R. Salsmans and G. Van Binst, *Tetrahedron*, 1974, **30**, 3059; (d) D. Tourwé, W. Van den Brandt, and G. Van Binst, *Bull. Soc. Chim. Belg.*, 1978, **87**, 427; (e) M. Čížková, V. Kolivoška, I. Císařová, D. Šaman, L. Pospíšil, and F. Teplý, *Org. Biomol. Chem.*, 2011, **9**, 450.
- M. Ohba, Y. Shinbo, M. Toda, and T. Fujii, *Chem. Pharm. Bull.*, 1992, **40**, 2543.

4. For the evaluation of the inhibitory activity against topoisomerase I, see: K. Suzuki, T. Okawara, T. Higashijima, K. Yokomizo, T. Mizushima, and M. Otsuka, *Bioorg. Med. Chem. Lett.*, **2005**, *15*, [2065](#) and references cited therein.
5. (a) J. P. Wolfe, R. A. Rennels, and S. L. Buchwald, *Tetrahedron*, **1996**, *52*, [7525](#); (b) B. H. Yang and S. L. Buchwald, *Org. Lett.*, **1999**, *1*, [35](#); (c) E. L. Cropper, A.-P. Yuen, A. Ford, A. J. P. White, and K. K. Hii, *Tetrahedron*, **2009**, *65*, [525](#); (d) V. A. Ignatenko, N. Deligonul, and R. Viswanathan, *Org. Lett.*, **2010**, *12*, [3594](#).
6. (a) A. Klapars, X. Huang, and S. L. Buchwald, *J. Am. Chem. Soc.*, **2002**, *124*, [7421](#); (b) A. Klapars, J. C. Antilla, X. Huang, and S. L. Buchwald, *J. Am. Chem. Soc.*, **2001**, *123*, [7727](#).
7. K. Yamazaki, Y. Nakamura, and Y. Kondo, *J. Chem. Soc., Perkin Trans. 1*, **2002**, [2137](#).
8. (a) A. B. Turner, 'Synthetic Reagents,' Vol. 3, ed. by J. S. Pizey, Ellis Horwood Ltd., Chichester, 1977, Chapter 2; (b) D. R. Buckle, 'Handbook of Reagents for Organic Synthesis: Oxidizing and Reducing Agents,' ed. by S. D. Burke and R. L. Danheiser, John Wiley & Sons Ltd., Chichester, 1999, pp. 137–141; (c) P. P. Fu and R. G. Harvey, *Chem. Rev.*, **1978**, *78*, [317](#).
9. (a) C. L. Nesloney and J. W. Kelly, *J. Org. Chem.*, **1996**, *61*, [3127](#); (b) G. M. Ksander, R. de Jesus, A. Yuan, R. D. Ghai, A. Trapani, C. McMartin, and R. Bohacek, *J. Med. Chem.*, **1997**, *40*, [495](#).
10. For convenience, each skeletal atom in the 3,4-dimethoxyphenyl moiety is indicated by a usual number and each aromatic carbon in the 2-bromophenyl moiety by a primed number.
11. S. Melnes, A. Bayer, and O. R. Gautun, *Tetrahedron*, **2012**, *68*, [8463](#).
12. M. D. Meyer, J. F. DeBernardis, and A. A. Hancock, *J. Med. Chem.*, **1994**, *37*, [105](#).
13. D. L. Musso, G. F. Orr, F. R. Cochran, J. L. Kelley, J. L. Selph, G. C. Rigdon, B. R. Cooper, and M. L. Jones, *J. Med. Chem.*, **2003**, *46*, [409](#).
14. D. Pflästerer, E. Rettenmeier, S. Schneider, E. de Las Heras Ruiz, M. Rudolph, and A. S. K. Hashmi, *Chem. Eur. J.*, **2014**, *20*, [6752](#).
15. (a) S. Kano, T. Yokomatsu, and S. Shibuya, *Chem. Pharm. Bull.*, **1975**, *23*, [1098](#); (b) Z. Vincze, A. B. Bíró, M. Csékei, G. Timári, and A. Kotschy, *Synthesis*, **2006**, [1375](#); (c) H. Lebel, C. Ladjel, and L. Bréthous, *J. Am. Chem. Soc.*, **2007**, *129*, [13321](#).
16. S. Chaudhary and W. W. Harding, *Tetrahedron*, **2011**, *67*, [569](#).
17. See ref. 3 for ¹H-NMR spectral data of the corresponding iodide (**2a**: X = I).